Shared on 07 May 25
Fair value Decreased 4.33%Falling Vaccine Demand And Looming Regulatory Risks Will Crush Value
AnalystLowTarget has decreased revenue growth from -14.0% to -16.2%.
Shared on 30 Apr 25
Fair value Decreased 2.21%Losses And mRNA Risks Will Curtail Progress Yet Hint Recovery
AnalystLowTarget made no meaningful changes to valuation assumptions.